A National Phase I Study of Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2019
At a glance
- Drugs Cabozantinib (Primary) ; Isotretinoin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 02 Jan 2019 Planned End Date changed from 1 Sep 2020 to 1 May 2021.
- 02 Jan 2019 Planned primary completion date changed from 1 Sep 2019 to 1 May 2020.
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.